BriaCell Therapeutics Corp. - Common Shares (BCTX)
5.0200
-0.5500 (-9.87%)
Briacell Therapeutics Corp is a biotechnology company focused on developing innovative immunotherapies to treat cancer, particularly breast cancer
The company specializes in creating personalized therapeutic approaches that harness the body’s immune system to target and eliminate cancer cells. Through its proprietary technology, Briacell aims to improve treatment outcomes for patients by enhancing the efficacy and safety of existing therapies, ultimately striving to bring new and effective cancer treatment options to the market. Their commitment to advancing cancer care is reflected in their rigorous research and clinical development efforts.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
BriaCell Therapeutics stock rises on positive Phase 2 trial results showing improved survival in late-stage metastatic breast cancer patients treated with Bria-IMT and an immune checkpoint inhibitor.
BriaCell Therapeutics Corp (NASDAQBCTX) reported preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell's Bria-IMT regimen: patients that have developed resistance to (and failed to respond to)
From my analysis of BriaCell, it would make a great buy and hold investment. If, and when, it is bought out by a major pharmaceutical company, or brings a product directly to market itself, its stock price should go up dramatically.
Registration study success could lead to a Biologics License Application (BLA) submission and commercialization approvals for BriaCell’s novel immunotherapy approach.
The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption.
